WEE1 and ovarian cancer: Fang et al. recently reported that the synergistic nature of PARP and Wee1 inhibitors was maintained while minimizing toxicity when sequential rather than concurrent therapies were employed in ovarian cancer xenograft and patient-derived xenograft models (10).